Rémy Cointreau (RMC) Q4 24/25 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 TU earnings summary
29 Nov, 2025Executive summary
Full-year sales reached €984.6 million, down 18% organically and 17.5% reported, in line with expectations, with Q4 down 19% due to technical and market factors, especially in China and APAC, while the US rebounded from a low base.
Cost optimization and cost-cutting measures delivered over €50 million in savings, supporting the confirmed 2024-25 COP organic margin target.
The 2029-30 strategic plan and long-term financial targets remain unchanged.
Financial highlights
Full-year sales were €984.6 million, down €209.6 million or -17.5% reported, with an organic decline of €215.3 million (-18%).
Volume effect was -11.8% and price/mix -6.3% for the year; currency translation added €5.7 million (0.5%).
Q4 Cognac sales fell 32.8% organically, while Liqueurs & Spirits grew 16.1% organically in Q4.
Outlook and guidance
FY 2024-25 organic COP margin expected between 21% and 22%, with exchange rates expected to add €5 million to COP.
2025-26 expected to resume high single-digit annual organic sales growth and gradual COP margin improvement, but margin improvement depends on tariff outcomes.
2029-30 targets reiterated: 72% gross margin and 33% COP margin.
Latest events from Rémy Cointreau
- Q3 organic sales up 2.8% as U.S. and EMEA gains offset APAC and China weakness.RMC
Q3 2026 TU3 Feb 2026 - Q1 sales dropped 15.6% organically, with gradual recovery and cost controls underway.RMC
Q1 24/25 TU3 Feb 2026 - Sales and profit dropped, but cost savings and recovery with high single-digit growth are targeted.RMC
H2 23/241 Feb 2026 - H1 sales dropped 15.9% organically, triggering revised guidance and a major cost-cutting plan.RMC
H1 24/25 TU18 Jan 2026 - Sales and profit dropped, but margins held up due to aggressive cost controls.RMC
H1 24/2512 Jan 2026 - Q3 sales fell 21.5% organically; full-year decline near 18% with margin guidance held.RMC
Q3 24/25 TU9 Jan 2026 - Sales and profit declined, but transformation and investment in recovery continue.RMC
H1 25/2627 Nov 2025 - Sales and profit fell sharply, but cost savings and a US rebound support cautious optimism.RMC
H2 24/2521 Nov 2025 - H1 sales dropped 4.2% organically, prompting a guidance cut amid China and currency headwinds.RMC
Q2 25/26 TU31 Oct 2025